Lung Function and Organ Dysfunctions in 178 Patients Requiring Mechanical Ventilation During The 2009 Influenza A (H1N1) Pandemic

Table 1 Baseline characteristics at admission of the entire group, and comparisons between survivors and non-survivors.

	All (n= 178)	Survivors (n= 93; 52%)	Non-survivors (n= 85; 48%)	P-value
Age	44 ± 15	45 ± 16	43 ± 15	0.36
Male gender	98 (55%)	49 (53%)	49 (58%)	0.44
APACHE II	18 ± 7	17 ± 6	20 ± 7	0.001
SOFA	4 (5 to 8)	3 (5 to 7)	6 (4 to 8)	0.000
Days of symptoms	6.7 ± 4.3	5.8 ± 3	7.5 ± 5	0.014
BMI	28 ± 8	28 ± 6	29 ± 10	0.32
Obesity¹	46 (26%)	17 (18%)	29 (34%)	0.016
COPD	28 (16%)	16 (17%)	12 (14%)	0.57
Asthma	10 (6%)	6 (6%)	4 (5%)	0.61
Other respiratory disease	5 (3%)	1 (1%)	4 (5%)	0.14
Chronic heart failure	10 (6%)	3 (3%)	7 (8%)	0.15
Other cardiac disease	8 (4%)	6 (6%)	2 (2%)	0.19
Ethilism/alcoholism	12 (7%)	8 (9%)	4 (5%)	0.30
Chronic hepatic disease	7 (4%)	1 (1%)	6 (7%)	0.04
Diabetes	16 (9%)	5 (5%)	11 (13%)	0.08
Chronic renal failure	13 (7%)	5 (5%)	8 (9%)	0.31
Immunosupression²	29 (16%)	10(11%)	19(22%)	0.04
Pregnancy	16 (9%)	7 (8%)	9 (11%)	0.47
Previous seasonal influenza vaccination	4 (4%)	2 (2%)	2 (2%)	0.93
Confirmed cases by RT-PCR testing	95 (53%)	49 (53%)	46 (54%)	0.85
Oseltamivir use³	174 (98%)	91 (98%)	82 (67%)	0.58
Corticosteroid use⁴	75 (42%)	40%	45%	0.51
Length of MV	10 (6 to 17)	11 (6 to 19)	10 (4 to 16)	0.05
LOS_ICU	12 (7 to 19)	14 (10 to 22)	10 (4 to 16)	< 0.001
LOS_HOSPITAL	16 (10 to 23)	21 (14 to 38)	11 (6 to 18)	< 0.001

BMI, body mass index; ICU, intensive care unit; LOS_ICU, length of stay at the ICU, in days; LOS_HOSPITAL, length of stay at the hospital, in days; MV, mechanical ventilation
¹ Obesity was defined as a BMI > 30
² Includes neoplasia, infection by human immunodeficiency virus, and autoimmune disease.
³ For corresponding doses, see reference 14.
⁴ Corticosteroids were prescribed in 36% of patients for septic shock as 300 mg/day of hydrocortisone. Ten percent received metilprednisolone for persistent ARDS; 3% for other reasons, and 2% were pregnant patients receiving antenatal dexametasone to accelerate maturation of fetal lungs.

ISSN: 1364-8535